June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees in the ceremony were: Jiajiong Zhang, Deputy Mayor of Lianyungang City, Yuan Yin, Deputy Director of the Management Committee of Lianyungang Economic and Technological Development Zone, Rui Ding, Secretary of the Party Committee and Chairman of Lianyungang Industrial Investment Group Co., Ltd.,  Lulin Zhang, General Manager and members of the leadership team of Lianyungang Industrial Investment Group, Ms. Claire Wu, Chairman and CEO of Beimei Pharma, Peng Ren, Chief Technology Officer and Deputy General Manager of Beimei Pharma, and Yan Zhang, Deputy General Manager of Beimei Pharma.

The successful settlement in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone is an important milestone for Beimei Pharma in the layout of pharmaceutical production. As Beimei Pharma's first self-built production base, the total investment reaches 600 million yuan, with the plan of designing a number of high-end children's pharmaceutical production lines as well as R&D facilities, office, testing facilities, warehouse and so on.

The base will be constructed in two phases. The first phase, the construction of No. 6 standard plant has been completed. This plant will begin to undertake the production of foreign and self-developed products in 2024. The second phase, the construction of 40 Chinese acres of land is scheduled to be customized in 2025. Beimei will continue to enhance its endogenous power.

Rui Ding, Secretary of the Party Committee and Chairman of Lianyungang Industrial Investment Group Co., Ltd., said.

 "Beimei Pharma focuses on the field of children's medicines and will become an important supplement to Lianyungang's pharmaceutical industry. We hope that through this cooperation, we can jointly promote the high-quality development of the children's medicine industry. ”

Ms. Claire Wu, Chairman and CEO of Beimei Pharma, said.

 "For Beimei Pharma, we took the most important step today. With our own production base, we finally will be able to undertake the production of foreign and self-developed products next year. We are very grateful to the leaders, the Management Committee and the Industrial Investment Group in Lianyungang City for their support and trust!"

After more than ten years of efforts, we have transformed magnificently. With the expansion of the company's scale, Beimei Pharma has entered into a new starting point and a new journey. In the future, the company will continue to develop products with large-scale, high-quality, and continuous innovation as the standard, focusing on meeting unmet needs of patients. We will continue to work hard towards the direction of becoming a leading Chinese pediatric drug company covering the entire industry chain of R&D, production and sales!

About Lianyungang International Pharmaceutical Innovation Industrial Park

Jiangsu Lianyungang International Pharmaceutical Innovation Industrial Park covers an area of about 1,000 Chinese acres, with a total investment of about 5 billion RMB and a total construction area of about 900,000 ㎡. The Industiral park is located in the Lianyungang Free Trade Pilot Zone and is an important part of Lianyungang's "Chinese Medicine Port". The industry is known as "The core of China's pharmaceutical innovation is in Jiangsu, and the core of Jiangsu's pharmaceutical innovation is in Lianyungang.".

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. 

For more information, please visit our website at http://www.beimeiyaoye.com